Empagliflozin (Jardiance) for type 1 diabetes – adjunctive therapy

NIHR HSRIC

Record Status
This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Authors' conclusions
Type 1 diabetes occurs when the person's own immune system attacks the pancreas and destroys the cells that produce a hormone called insulin, which is needed to regulate the body's sugar levels. Without insulin, there is too much sugar in the blood. This can cause damage to the eyes, nerves, kidneys and other tissues, and can increase the chances of heart attacks and strokes. Empagliflozin is a drug currently used to treat type 2 diabetes. It is given as a tablet that is taken once daily. Empagliflozin is currently being studied to see if it would also work in patients with type 1 diabetes, to be taken alongside the insulin injections that patients already take. If licensed in the UK, empagliflozin will offer type 1 diabetes patients an additional treatment option alongside insulin to maintain stable sugar levels.

Final publication URL
http://www.hsric.nihr.ac.uk/topics/empagliflozin-jardiance-for-type-1-diabetes-adjunctive-therapy/

Indexing Status
Subject indexing assigned by CRD

MeSH
Humans; Benzhydryl Compounds; Diabetes Mellitus, Type 1; Glucosides

Language Published
English

Country of organisation
England

English summary
An English language summary is available.

Address for correspondence
NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk

AccessionNumber
32016000819

Date abstract record published
22/06/2016